Henlius Present Results of HLX03 (biosimilar, adalimumab) in P-lll Study for Plaque Psoriasis at EADV 2020

Shots:

• The P-III HLX03-Ps03 study involves comparing the efficacy, safety and immunogenicity assessing of HLX03 (80mg, qd) with reference adalimumab in 262 Chinese patients in the ratio of (1:1) with moderate to severe plaque psoriasis
• Result: On 1EPs % improvement of PASIwk16 (83.48% vs 82.02%), least square mean difference (1.46%), no significant differences between the treatment groups in 2EPs that include PASI 75, PGA reaching clearance and change in DLQI
• HLX03 is an adalimumab biosimilar to be used for the treatment of autoimmune diseases including psoriasis, RA & AS

Click here to­ read the full press release/ article | Ref: Henlius | Image: BioSpectrum Asia